KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $114.48M |
| Gross Profit (TTM) | $58.47M |
| EBITDA | $-138.45M |
| Operating Margin | -57.40% |
| Return on Equity | -190.20% |
| Return on Assets | -61.00% |
| Revenue/Share (TTM) | $2.11 |
| Book Value | $-0.38 |
| Price-to-Book | 49.03 |
| Price-to-Sales (TTM) | 12.56 |
| EV/Revenue | 914.43 |
| EV/EBITDA | -3.53 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 30.70% |
| Shares Outstanding | $53.24M |
| Float | $38.18M |
| % Insiders | 1.72% |
| % Institutions | 136.88% |
Volatility is currently contracting
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben Palleiko, Chief Executive Officer of KalVista. “Currentl.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are.
MILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Chiesi Group. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating KalVista Pharmaceuticals, Inc. (NASDAQ: KALV ) related to its sale to Chiesi Group. Under the terms of the proposed transaction, KalVista shareholders are expected to receive $27.00 per share in cash. Is it a fair deal?
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) to Chiesi Group for $27.00 per share in cash. Halper Sadeh encourages KalVista shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether KalVista and its board of directors.
Italy's Chiesi has agreed to buy KalVista Pharmaceuticals for about $1.9 billion, the company said on Wednesday, as it looks to grow its rare disease drug portfolio.
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15 a.m. EST A live audio webcast of the presentation will be accessible on the Investors section of the Company's website at www.ir.kalvista.com/event-calendar. An archived replay will be available approximately two hours after the completion of.
KalVista Pharmaceuticals is now a commercial rare-disease play with Ekterly established as the first oral on-demand HAE therapy across seven approved markets. I think Ekterly's convenience versus injectables supports future adoption. Repeat refills have also been a favorable tailwind. Looking ahead, Ekterly's potential pediatric expansion into ages 2 to 11 could add meaningful upside.
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
